ripk1

RIPK1-IN-9 is a potent and selective inhibitor of RIPK1, a dihydronaphthone compound, which inhibits U937 and L929 cells with an IC50 of 2 nM and 1.3 nM, respectively.

RIPK1-IN-7 is a potent and selective inhibitor of RIPK1 (Kd of 4 nM and enzymatic IC50 of 11 nM), exhibiting excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model.

PK68 is an effective and selective inhibitor of type II receptor-interacting kinase 1 (RIPK1, IC50 = 90 nM). PK68 can be used for research on the treatment of inflammatory disorders and cancer metastasis.

RIPK3-IN-1 is a selective and potent RIPK3 inhibitor (IC50: 9.1 nM) that inhibits the activities of c-Met kinase, RIPK1 and RIPK2.RIPK3-IN-1 has potential tumorigenic activity and can be used to study apoptosis.

ICCB-19 hydrochloride (ICCB-19 HCl) is an inhibitor of TRADD (TNFRSF1A Associated Via Death Domain). It binds to a pocket on the N-terminal TRAF2-binding domain of TRADD (TRADD-N), which interacts with the C-terminal domain (TRADD-C) and TRAF2 to modulate the ubiquitination of RIPK1 and beclin 1.

Apostatin-1 (Apt-1) is a novel TRADD inhibitor that binds to a pocket on the N-terminal TRAF2 binding domain of TRADD.

RIPK1-IN-4 is a potent and selective type II kinase receptor interacting protein 1 (RIP1) kinase inhibitor and binds to a DLG-out inactive form of RIP1 (IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase).

RIPK1-IN-3 is a RIPK1 inhibitor, with anti-inflammatory proprieties.

RIPK1-IN-25 (WL8) is a RIPK1 inhibitor with blood-brain barrier permeability, displaying an EC50 of 19.9 nM and a Kd of 25 nM. It is utilized in the research of neurodegenerative diseases.

RIPK1-IN-24 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) with an IC50 of 1.3 μM. It is utilized in research on inflammatory diseases.

RIPK1-IN-26 is a potent inhibitor of Receptor-Interacting Serine Threonine Kinase 1 (RIPK1), exhibiting anti-necrotic properties in cells. This compound demonstrates good metabolic stability and binding specificity in mice. RIPK1-IN-26 holds potential for development as a PET imaging probe and in the research of neurodegenerative diseases.

RIPK1-IN-27 (compound 19) is an inhibitor of RIPK1.

RIPK1-IN-28 (compound 13) is an orally active inhibitor of RIPK1. It exhibits inhibitory effects on human I2.1 and Hepa1-6 cells, with IC50 values of 0.4 and 1.2 nM, respectively.

RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor with an IC50 of 6.9 nM. It exhibits anti-necroptotic apoptosis activity by inhibiting RIPK1. In a TNF-α induced inflammatory in vivo model, a 10 mg/kg dose of RIPK1-IN-29 can protect mice from hypothermia and death. This compound is suitable for research in the field of inflammatory diseases.

RIPK1-IN-30 (compound 24) is a potent RIPK1 inhibitor with an IC50 of 2.01 μM. It demonstrates a protective effect in the HT-29 cell model of TSZ-induced necroptosis, with an EC50 of 6.77 μM.

RIPK1-IN-15 (Compound 2.5) is a potent RIPK1 inhibitor with potential applications in research on neurodegenerative, autoimmune, and inflammatory diseases [1].

RIPK1-IN-13 (Compound 8) is an effective RIPK1 inhibitor (IC50=1139 nM) that can block the activation of the necrotic apoptosis pathway, holding research potential in inflammatory diseases.

RIPK1-IN-14 (Compound 41) is a potent RIPK1 inhibitor (IC50: 92 nM) with significant anti-necrotic apoptotic effects in a necrotic apoptosis model using U937 cells.

RIPK1-IN-12 is a potent inhibitor of RIPK1, exhibiting an inhibitory effect on necroptosis in human and mouse cells with EC50 values of 1.6 and 2.9 nM, respectively.

RIPK1-IN-11 is an orally active RIPK1 inhibitor with a Kd value of 9.2 nM and an IC50 value of 67 nM. RIPK1-IN-11 inhibits necrosis in human and mouse cells and exhibits anti-inflammatory effects.

RIPK1-IN-8 is an aminoimidazolopyridine and is a selective and potent inhibitor of RIPK1 (IC50: 4 nM).RIPK1-IN-8 has research potential in inflammatory diseases.

RIPK1-IN-10 is a potent inhibitor of receptor-interacting protein kinase 1 (RIPK1).

RIPK1-IN-17 is a dual inhibitor of RIPK1 and RIPK3 that specifically inhibits necrosis by inhibiting phosphorylation of RIPK1, RIPK3 and MLKL, protecting mice from hypothermia and death in a tnf-induced inflammation model.

RIPK1-IN-16 is an orally active, potent RIPK1 inhibitor that mitigates excessive inflammation via inhibition of RIPK1-mediated necroptosis in vivo, protecting mice from TNF-induced systemic inflammatory response syndrome and sepsis [1].